Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Anti-respiratory virus medicine and use

A virus and drug technology, applied in the direction of antiviral agents, medical preparations containing active ingredients, pharmaceutical formulations, etc., to achieve the effects of good tolerance, convenient use and low toxicity

Inactive Publication Date: 2007-12-12
WUHAN UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the effect of this drug on anti-coxsackie virus B3, adenovirus Ad7, parainfluenza virus and rhinovirus has not been reported or discovered yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-respiratory virus medicine and use
  • Anti-respiratory virus medicine and use
  • Anti-respiratory virus medicine and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1: Arbidol hydrochloride is to the cytotoxicity of HEp-2 cell and HEL cell

[0023] Use trypsin to disperse well-grown HEp-2 cells and HEL cells into a single cell suspension, press 1×10 5 / ml concentration in 96-well plate, 0.1ml per well, set at 37°C, 5% CO 2 Cultivate in the incubator for 24h. After the cells grow into a single layer, the supernatant of the culture medium is discarded and replaced with a drug-containing maintenance solution of different concentrations. Four replicate wells are set for each concentration, and normal cells are set as a control. Continue culturing for 48 h, discard the culture supernatant, add 50 μl of serum-free MEM medium containing 5 mg / ml MTT (tetramethylazozolium salt) to each well, and place in CO 2 After continuing to culture in the incubator for 2-3 hours, discard the MTT supernatant, wash 3 times with PBS, add 100 μl of dissolving solution (DMSO:ethanol volume ratio: 1:1) to each well, shake for 5-10 minutes, and s...

Embodiment 2

[0033] Embodiment 2: Arbidol hydrochloride anti-Coxsackie virus effect in vitro

[0034] It is proposed that the effect of Arbidol hydrochloride on CVB3 is divided into four groups. Group I (drug antiviral biosynthesis group): first add virus liquid to adsorb cells for 2 hours, then add drug-containing maintenance liquid. Group II (drug direct action group): the virus solution reacted with different concentrations of drugs for 2 hours, and then the mixed solution was incubated with the cells for 2 hours, and then the cell maintenance solution was replaced. Groups III and IV (drug antiviral adsorption 2h, 8h groups): After adding different concentrations of drugs into the cells for 2h and 8h respectively, the drug solution was discarded, and the virus solution was added, and the cell maintenance solution was replaced after 2 hours of adsorption.

[0035]Four replicate wells were set in each well of the above four experimental groups, and uninfected cell control, virus control ...

Embodiment 3

[0044] Embodiment 3: Arbidol hydrochloride anti-adenovirus Ad7 effect in vitro

[0045] It is proposed that the effect of Arbidol hydrochloride on adenovirus Ad7 is divided into four groups. Group I (drug antiviral biosynthesis group): first add virus liquid to adsorb cells for 2 hours, then add drug-containing maintenance liquid. Group II (drug direct action group): the virus solution reacted with different concentrations of drugs for 2 hours, and then the mixed solution was incubated with the cells for 2 hours, and then the cell maintenance solution was replaced. Groups III, IV, and V (2h, 4h, and 8h groups of drug antiviral adsorption): add different concentrations of drugs into the cells for 2h, 4h, and 8h respectively, discard the drug solution, add virus solution, and absorb After 2 h, the cell maintenance solution was replaced.

[0046] Four replicate wells were set for each well of the above five groups of experimental groups, and uninfected cell control, virus contr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a chemical compound in general formula (I), wherein HO- is hydroxy, Br- is bromine, CH3- is methyl, CH2N(CH3)2- is dimethylaminomethyl, and COOC2H5- is acetoacetate. Medicinal composition with the chemical compound as active ingredient has evident antivirus action against Coxsackie b3 virus, adenovirus Ad 7, parainfluenza virus and rhinovirus. The drug has good antiviral activity against Coxsackie virus, adenovirus Ad 7, parainfluenza virus, and rhinovirus.

Description

[0001] Application date of the original case: April 26, 2005 [0002] Original application number: 200510018613.9 [0003] Original title of invention: a drug against respiratory virus and its use technical field [0004] The invention relates to a new antiviral drug Arbidol hydrochloride and the anti-multiple respiratory virus effects of the drug. Specifically, the present invention belongs to a new compound with good antiviral activity, and the application of the compound in the preparation of anti-coxsackie virus B3, adenovirus Ad7, parainfluenza virus and rhinovirus drugs. Background technique [0005] Influenza and acute respiratory virus infection are diseases with a high clinical incidence and a wide range of diseases. Due to the antigenic variability of influenza virus and its multi-drug resistance, a safe and effective drug for treatment and prevention is urgently needed. Chemical drugs play an extremely important role in the treatment of influenza and ARVI. So f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/404A61P31/16
Inventor 杨占秋熊海蓉何静石丽桥关意洪肖红
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com